DEVELOPMENT OF A FORMULATION-AGNOSTIC AUTOINJECTOR PLATFORM

The Department of Defense, through the Joint Project Manager for CBRN Medical, is seeking innovative designs for a formulation-agnostic autoinjector platform capable of delivering a wide range of pharmaceutical formulations including single-chamber liquids, dual-chamber liquid-liquid mixtures, and dual-chamber solid-liquid reconstitutions. The device must meet an extraordinary reliability standard of 99.999% over its lifecycle, validated to FDA requirements, and operate robustly across fluid volumes from 0.4 mL to 5.0 mL while accommodating varying viscosities without retooling the production line. It must be ruggedized to withstand MIL-STD-810H environmental conditions and ensure reliable intramuscular delivery through standard military protective gear including MOPP suits and ACU uniforms. Initial target therapeutics include Atropine, Pralidoxime Chloride, Midazolam, and Naloxone, critical for CBRN medical response. The project emphasizes dual-use commercial potential, encouraging designs that can sustain viability beyond government procurement to serve broader medical markets. The initiative is structured as a sources-sought notice under solicitation number W911SR-26-PLATFORM, with responses due by August 7, 2026, and is intended for market research rather than a binding solicitation. The effort is managed by the office located at Aberdeen Proving Ground, Maryland, with primary point of contact Imani Daiyaan and secondary contact Alex M. Schupp. The place of performance is Gunpowder, Maryland, and the NAICS code 339112 reflects the classification for medical device and equipment manufacturing. All submissions are evaluated for technical feasibility, scalability, and alignment with military and civilian application needs.